138 related articles for article (PubMed ID: 24618606)
1. Observations on Aron et al's "Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3 CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia".
Fellegara G; Gabba S; Dorji T; De Luca G; Colecchia M
Am J Surg Pathol; 2014 Jul; 38(7):1013-5. PubMed ID: 24618606
[No Abstract] [Full Text] [Related]
2. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
[TBL] [Abstract][Full Text] [Related]
3. CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.
Neal DJ; Amin MB; Smith SC
Diagn Pathol; 2020 May; 15(1):61. PubMed ID: 32456709
[TBL] [Abstract][Full Text] [Related]
4. Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Alston ELJ; Zynger DL
Diagn Pathol; 2019 Aug; 14(1):91. PubMed ID: 31419984
[TBL] [Abstract][Full Text] [Related]
5. Dysplasia and carcinoma in situ of the urinary bladder.
Lopez-Beltran A; Marques RC; Montironi R; Reymundo C; Fonseca J; Cheng L
Anal Quant Cytopathol Histpathol; 2015 Feb; 37(1):29-38. PubMed ID: 26072632
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
[TBL] [Abstract][Full Text] [Related]
7. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
[TBL] [Abstract][Full Text] [Related]
8. Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?
Di Sciascio L; Ambrosi F; Franceschini T; Giunchi F; Franchini E; Massari F; Bianchi FM; Colecchia M; Fiorentino M; Ricci C
Pathol Res Pract; 2022 Jun; 234():153937. PubMed ID: 35561522
[TBL] [Abstract][Full Text] [Related]
9. Urothelial carcinoma in situ: diagnostic update.
McKenney JK
Pathology; 2021 Jan; 53(1):86-95. PubMed ID: 33234229
[TBL] [Abstract][Full Text] [Related]
10. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center.
McIntire P; Khan R; Kilic I; Wojcik EM; Pambuccian SE; Barkan GA
Ann Diagn Pathol; 2019 Aug; 41():124-128. PubMed ID: 31238192
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ.
Yoo D; Min KW; Pyo JS; Kim NY
Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763728
[No Abstract] [Full Text] [Related]
13. Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium.
Yin H; He Q; Li T; Leong AS
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):260-5. PubMed ID: 16932015
[TBL] [Abstract][Full Text] [Related]
14. Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
[TBL] [Abstract][Full Text] [Related]
15. CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia.
Arias-Stella JA; Shah AB; Gupta NS; Williamson SR
Arch Pathol Lab Med; 2018 Jan; 142(1):64-69. PubMed ID: 28967804
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and meta-analysis of CK20, CD44, Ki67 and p53 as immunohistochemical markers in bladder carcinoma in situ.
Straccia P; Fiorentino V; Martini M; Pierconti F
Actas Urol Esp (Engl Ed); 2022 Nov; 46(9):521-530. PubMed ID: 36216762
[TBL] [Abstract][Full Text] [Related]
17. Urothelial dysplasia of the bladder: diagnostic features and clinical significance.
Lopez-Beltran A; Montironi R; Vidal A; Scarpelli M; Cheng L
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):121-9. PubMed ID: 24344498
[TBL] [Abstract][Full Text] [Related]
18. Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.
Bahceci D; Nguyen JK; Sangoi AR; Stohr BA; Chan E
Hum Pathol; 2023 Jun; 136():56-62. PubMed ID: 36997033
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and immunologic diagnosis of cancer. Renal and transitional carcinomas.
Cordon-Cardo C
Tumour Biol; 1987; 8(2-3):94-102. PubMed ID: 3329405
[No Abstract] [Full Text] [Related]
20. Prevalence of hematuria in urothelial neoplasia.
Shenoy UA; Schumann GB; DeBellis CC
Am J Clin Pathol; 1986 Jan; 85(1):80-2. PubMed ID: 3940425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
